Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey.

Maryia ZhdanavaH Lynn Starr Todor I TotevPatrick LefebvreAditi ShahKristy ShengDominic Pilon

Published in: Neuropsychiatric disease and treatment (2022)

LAI prescribing and prescriber-reported antipsychotic adherence in patients with schizophrenia remained largely unchanged approximately one year after the start of COVID-19. Focused efforts to overcome patients' COVID-19 vaccine hesitancy are warranted.

Keyphrases

coronavirus disease
sars cov
primary care
end stage renal disease
ejection fraction
chronic kidney disease
bipolar disorder
prognostic factors
cross sectional
emergency department
type diabetes
adipose tissue
metabolic syndrome
quality improvement
skeletal muscle
patient reported